John MBA - Vor Biopharma Chief Development
| VOR Stock | USD 1.50 0.04 2.74% |
Executive
John MBA is Chief Development of Vor Biopharma
| Age | 49 |
| Address | 100 Cambridgepark Drive, Cambridge, MA, United States, 02140 |
| Phone | 617 655 6580 |
| Web | https://www.vorbio.com |
Vor Biopharma Management Efficiency
The company has Return on Asset of (0.3974) % which means that on every $100 spent on assets, it lost $0.3974. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.7807) %, meaning that it generated no profit with money invested by stockholders. Vor Biopharma's management efficiency ratios could be used to measure how well Vor Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/07/2025, Return On Tangible Assets is likely to drop to -0.56. In addition to that, Return On Capital Employed is likely to drop to -0.83. At this time, Vor Biopharma's Net Tangible Assets are relatively stable compared to the past year. As of 02/07/2025, Non Current Assets Total is likely to grow to about 69.2 M, while Other Current Assets are likely to drop slightly above 3.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Chad Morin | Kiniksa Pharmaceuticals | N/A | |
| Anna Rivkin | Foghorn Therapeutics | N/A | |
| JD Esq | Kymera Therapeutics | 66 | |
| Michael Alonso | Bolt Biotherapeutics | N/A | |
| Carsten MBA | Kiniksa Pharmaceuticals | 59 | |
| Mary Fenton | Cullinan Oncology LLC | 60 | |
| Heba Nowyhed | Arcellx | N/A | |
| Edmund Dunn | Monte Rosa Therapeutics | 59 | |
| Myesha Lacy | Arcellx | N/A | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Matthew Metivier | Nuvalent | N/A | |
| Mary CPA | Cullinan Oncology LLC | 61 | |
| Robert Shoemaker | Erasca Inc | 44 | |
| Michael Varney | Erasca Inc | 67 | |
| Thomas PharmD | Shattuck Labs | N/A | |
| John Moore | Edgewise Therapeutics | 60 | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| David Brochu | Autolus Therapeutics | 69 | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Corinne Noyes | Lyra Therapeutics | 56 | |
Management Performance
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.4 |
Vor Biopharma Leadership Team
Elected by the shareholders, the Vor Biopharma's board of directors comprises two types of representatives: Vor Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vor. The board's role is to monitor Vor Biopharma's management team and ensure that shareholders' interests are well served. Vor Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vor Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| PharmD D, Chief Officer | ||
| Samir MS, Senior Management | ||
| Han MD, Chief Officer | ||
| Dr MBA, Chief Officer | ||
| Eyal MD, Chief Officer | ||
| Tania Philipp, Chief Officer | ||
| MBA MD, CEO Pres | ||
| Pharm PharmD, Chief Officer | ||
| Amy Quinlan, Interim Officer | ||
| Veit Schmelmer, VP Management | ||
| John MBA, Chief Development | ||
| David MBA, Senior Quality | ||
| Tirtha Chakraborty, Chief Officer | ||
| DPHIL MD, Scientific Board |
Vor Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vor Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | 157.21 M | ||||
| Shares Outstanding | 124.78 M | ||||
| Shares Owned By Insiders | 1.17 % | ||||
| Shares Owned By Institutions | 81.20 % | ||||
| Number Of Shares Shorted | 1.15 M | ||||
| Price To Book | 2.57 X | ||||
| EBITDA | (114.37 M) | ||||
| Net Income | (117.86 M) |
Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.